Tumor necrosis factor-a (TNFa) decreased the expression of pulmonary surfactant proteins SP-A and SP-B in human pulmonary adenocarcinoma cell lines. The effect of TNFa on SP-A content and mRNA in the pulmonary adenocarcinoma cell line, H441-4, was concentration and time dependent.
1. Abbreviations used in this paper: ARDS, adult respiratory distress syndrome; Mn-SOD, manganese superoxide dismutase; SP-A, pulmonary surfactant protein-A; SP-B, pulmonary surfactant protein B; SP-C, pulmonary surfactant protein C; TNFa, tumor necrosis factor alpha.
SP-B, and SP-C, comprise < 10% of the total mass of surfactant, but are necessary for surfactant function ( 1-3) for review. Surfactant protein A, the most abundant surfactant protein, is synthesized and secreted primarily by alveolar type II epithelial cells. SP-A binds and aggregates surfactant phospholipids in the alveolus (4) and confers the unique structural organization of tubular myelin to surfactant lipids in the presence of calcium and surfactant protein B (5) . SP-B is a distinct hydrophobic surfactant peptide comprised of 79 amino acid residues and confers surfactantlike activity to phospholipids (2, 3) for review. SP-A and SP-B may also play an important role in surfactant metabolism. SP-A inhibits phospholipid secretion and enhances phospholipid reuptake by type II epithelial cells in vitro (6, 7) . SP-B enhances the uptake of phospholipids by type II cell in vitro (8) .
Deficiency or altered function of pulmonary surfactant is associated with several human diseases. Respiratory distress syndrome ofthe newborn, a leading cause ofneonatal morbidity and mortality, is associated with decreased pulmonary surfactant (9) . Adult respiratory distress syndrome (ARDS), a common cause of acute respiratory failure in adults, occurs after severe injury, shock, or infection. Whereas the pathogenesis of respiratory failure in patients with ARDS may vary with the heterogeneity of predisposing clinical conditions, abnormalities of surfactant composition and function have been described in ARDS (10, 11) .
Tumor necrosis factor is a 1 7,000-D peptide produced by monocytes and macrophages in response to bacterial lipopolysaccharide, interleukin-2, and various mitogens and was initially described by Carswell et al. as an endotoxin-induced serum factor that caused necrosis of solid tumors ( 12) . Subsequent to that report, diverse biological actions have been ascribed to TNFa (13) . TNFa is a potent mediator of immune function and inflammation. The effects of TNFa in vivo include fever, induction of interleukin-1, and activation of polymorphonuclear cells (14) . Beutler (14, 15) . Endotoxin increases synthesis and secretion of TNFa by monocytes and macrophages in vitro and in vivo (13) . Passive immunization against TNFa reduces the mortality associated with endotoxin challenge in rats (15) . Whereas the role of TNFa in the pathogenesis of ARDS has not been conclusively proven, infusion of TNFa causes pulmonary hemorrhage, edema, and inflammation (16) 7.4 with 0.5% Nonidet P-40). Each assay plate included a standard curve generated with purified human SP-A (1-100 ng/ml) and four serial dilutions of each cell and media sample. Horseradish peroxidase conjugated antirabbit sera was used for detection, and color developed with 0-phenylenediamine and H202. Absorbance was determined at 490 nm. Correlation coefficients of the standard curves were 0.95-0.99. Sample dilutions were adjusted to within the linear range of the assay. The SP-A content ofthe samples was expressed as a percentage ofthe SP with neutral red, a vital dye which is retained only by viable cells (20) . Uptake and retention of dye was not altered by TNFa.
Effect of TNFa on SP-A content and synthesis. TNFa decreased intracellular and extracellular SP-A content of the H44 1-4 cells. The amount of SP-A recovered in the media was decreased 48 h after addition of 25 ng/ml TNFa, from 891±302 ng/ml (mean±SD, n = 12) in control to 437±152 (mean±SD, n = 12) after treatment with TNFa. TNFa also decreased content of SP-A within the H441-4 cells (Fig. 1) . SP-A content was significantly decreased within 24 (Fig. 2 a) . TNFa, 1.0 ng/ml, significantly decreased SP-A mRNA (Fig. 2 a) . Fig. 2 b depicts the densitometric analysis of SP-A mRNA normalized to f-actin. TNFa neither changed the relative abundance of 3-actin mRNA nor altered the total amount of RNA recovered from the cells. The time course for the loss of SP-A mRNA was assessed after addition of 25 ng/ml TNFa (Fig. 3) . SP-A mRNA was markedly decreased 12 h after exposure to TNFa and was barely detectable after 24 h. When H44 1-4 cells were exposed to 25 ng/ml TNFa for 24 h, SP-A mRNA content was 21.6±4% of control, as assessed by densitometric analysis of Northern blots (Fig. 4) . TNFa also decreased SP-A mRNA in a distinct pulmonary adenocarcinoma cell line, NCI-H820. In contrast to the inhibitory effects of TNFa on SP-A mRNA, TNFa consistently increased Mn-SOD mRNA. The Mn-SOD mRNA was barely detectable in the absence of TNFa and increased markedly after exposure to TNFa for 48 h in both H441-4 (Fig. 5 a) and H820 (Fig. 5 b) cell lines. (Fig. 6) . SP-B mRNA was decreased within 6 h and was nearly undetectable 24 h after exposure to TNFa. noma cell lines. TNFa decreased SP-A mRNA in association with decreased cellular content of SP-A protein and decreased synthesis and secretion of SP-A. TNFa also decreased the abundance of the mRNA of another surfactant protein, SP-B. The specificity of the inhibitory effects of TNFa on expression of the surfactant proteins was supported by the finding that TNFa increased Mn-SOD expression and did not alter ,B-actin mRNA. The inhibitory effects TNFa on SP-A expression were distinct from interferon y which increased SP-A content in the H44 1 cell line.
The mechanisms involved in decreased SP-A expression after treatment with TNFa appear to be pretranslational. Decreased SP-A mRNA paralleled the decreased synthesis, secretion, and cellular content, suggesting that TNFa affected SP-A through altered gene expression. TNFa is known to alter expression of many proteins, including adipose cell lipogenic enzymes (26) and several muscle-specific genes including alpha cardiac actin and myosin heavy chain (27) . Torti et al. showed that the effects of TNFa on adipose cell genes were mediated by changes in gene transcription (26) . TNFa increased collagenase production in cultured fibroblasts (28).
Brenner and co-workers demonstrated that stimulation of collagenase gene transcription by TNFa was mediated by an element of the gene that is responsive to the transcription factor AP-1. They showed that TNFa produced a prolonged increase in jun gene transcription, and that jun protein interacted with the AP-1 site in the collagenase gene (29) .
Most cellular responses to TNFa are initiated by binding to a high-affinity cell surface receptor (30) (35) for review. In human fetal lung explant cultures, SP-A gene expression is stimulated by cAMP, EGF, y interferon, and glucocorticoids, although both inhibitory and stimulatory effects of glucocorticoids have been observed (17, 35, 36) . SP-A gene expression is inhibited by insulin (37) and TGF-j3 (38) . The extent to which transcriptional or posttranscriptional mechanisms control the various hormonal influences on SP-A gene expression remains to be more fully clarified. The finding that TNFa is a potent inhibitor of SP-A gene expression raises the possibility that locally produced monocyte and macrophage derived proteins, may regulate synthesis of surfactant protein A. In the present study, interferon -y stimulated SP-A expression in the H441 cell line, confirming its stimulatory effects on SP-A synthesis and mRNA previously documented in human fetal lung explant cultures (39) . The current results demonstrate that the effects of y interferon are mediated by direct action on the epithelial cells and therefore may be mediated by processes independent of the mesenchyme present in the explant tissues of human fetal lung. The present studies demonstrate that TNFa also decreases expression of SP-B mRNA in H441 pulmonary adenocarcinoma cells. SP-B is a hydrophobic surfactant protein that increases the rate of absorption of surfactant phospholipids to an air-liquid interface (40) for review. SP-B is expressed by developing epithelial cells ofthe human fetal lung and its expression is increased by glucocorticoids in the H441-4 and H820 cell lines (17, 18) , and in human fetal lung explants (41, 42) . The present findings, that TNFa inhibits both SP-A and SP-B expression are similar to the recently described effects of TPA (34a). In the rat, SP-A and SP-B mRNA increase coordinately during lung development (43); however, SP-A and SP-B mRNA are also subject to distinct regulatory influences (35) for review. Administration of TNFa (in vivo) to rodents causes a syndrome similar to septic shock and induces acute lung injury, respiratory insufficiency, and death (44) . Histopathologic examination of the lungs from TNFa-treated rodents revealed occlusion of large arteries by neutrophil-rich thrombi, margination of polymorphonuclear leukocytes, interstitial and peribronchiolar pneumonitis, and pleural effusions with alveolar edema (44) . Similar histologic alterations are observed in animals treated with endotoxin, and also resemble the pulmonary findings of patients with ARDS. The mechanisms by which infusion of TNFa causes acute lung injury are not completely understood. Activation of complement, induction of a procoagulant endothelial surface, and increased neutrophil production of superoxide anion or secretion oflysomal enzymes have all been observed after TNFa exposure (45) . The present work demonstrates a dramatic inhibitory effect of TNFa on surfactant protein expression. However, the current studies utilized pulmonary adenocarcinoma cell lines to study the effects of TNFa in vitro. Determination of the effects of TNFa on SP-A expression in vivo is complicated by the potential interactions among TNFa and other inflammatory mediators, including interferons, which may have complex and conflicting influences on surfactant protein expression. Whether the deleterious effects of TNFa on lung function in vivo are related to changes in pulmonary surfactant, and specifically to changes in surfactant proteins, remains to be clarified. Nevertheless, our current findings raise the possibility that inflammatory mediators may directly interact with respiratory epithelial cells to alter synthesis of important components of the surfactant system. 
